Drugs / Talikabtagene Autoleucel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07502118 | Sep 2025 → Feb 2028 expected | B-cell acute lymphoblastic leukemia, follicular lymphoma, high grade B-cell lymphoma | Health Institutes of Turkey | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Talikabtagene Autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07502118 ↗ |
| Modality | Cell therapy | “CAR-T cell therapy” NCT07502118 ↗ |
| Route | Intravenous | “infused intravenously” NCT07502118 ↗ |
| Target | CD19 | “anti-CD19 chimeric antigen receptor (CAR) T-cell product” NCT07502118 ↗ |